罗替高汀贴剂在帕金森病住院患者中的处方准确性、谵妄及临终使用评估
该研究回顾性评估英国教学医院2018年1月至2019年7月84例住院帕金森病患者罗替高汀贴剂使用情况,发现仅30%处方剂量与OPTIMAL Calculator 2推荐一致,37%偏高、33%偏低;24%出现新发或加重谵妄,10%出现新发或加重幻觉;70%患者评估时已死亡,其中25%经历终末躁动。
要点
- 仅30%住院帕金森病患者罗替高汀处方剂量与推荐一致,37%偏高、33%偏低。
- 24%出现新发或加重谵妄,10%出现新发或加重幻觉。
- 70%患者评估时已死亡,院内死亡者中25%经历终末躁动。
核心结论
- 口服多巴胺能药物急性转换为罗替高汀贴剂仍存在问题,即使有验证工具可用。
- 不适当剂量可能诱发或加重谵妄/幻觉。
- 罗替高汀在临终阶段的使用需进一步评估。
研究设计与样本
- 回顾性评估英国教学医院住院患者罗替高汀使用情况。
- 纳入2018年1月至2019年7月处方,分析住院记录。
- 以OPTIMAL Calculator 2作为口服多巴胺能药物转换为罗替高汀的金标准。
- 共纳入84例住院患者。
主要发现
- 25例(30%)处方剂量为推荐剂量,31例(37%)高于推荐,28例(33%)低于推荐。
- 41例痴呆患者中15例(37%)在启用罗替高汀前不适当接受较高剂量。
- 49例谵妄患者中22例(45%)在启用罗替高汀前不适当接受较高剂量。
- 20例(24%)出现新发或加重谵妄,8例(10%)出现新发或加重幻觉。
- 59例(70%)评估时已死亡,其中40例(68%)院内死亡,10例(25%)经历终末躁动。
关键数值与推荐
- 推荐剂量以OPTIMAL Calculator 2为金标准判定。
- 84例中仅25例(30%)处方剂量与推荐一致。
- 痴呆患者中37%(15/41)和谵妄患者中45%(22/49)不适当接受较高剂量。
- 新发或加重谵妄发生率24%(20/84),新发或加重幻觉发生率10%(8/84)。
- 院内死亡者中终末躁动发生率25%(10/40)。
临床怎么用
- 住院帕金森病患者急性转换罗替高汀时应使用OPTIMAL Calculator 2等验证工具核对剂量。
- 对痴呆或谵妄患者尤其需警惕不适当高剂量可能诱发或加重谵妄/幻觉。
- 临终阶段使用罗替高汀需谨慎评估终末躁动风险。
局限性
- 回顾性单中心研究,样本量84例。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotigotine patch, a trans-dermal dopamine agonist, is used acutely to replace oral dopaminergic medications for inpatients with Parkinson's disease where enteral routes are no longer available, and is also an option in end-of-life care where patients can no longer swallow. Concerns regarding acute use of Rotigotine include difficulty achieving dopaminergic equivalence, promotion of delirium/hallucinations and promotion of terminal agitation. OBJECTIVE: our objectives were to establish: (i) accuracy of Rotigotine prescribing, (ii) rates of delirium/hallucinations and (iii) rates of terminal agitation. METHOD: we retrospectively evaluated the use of Rotigotine in an inpatient population at a UK teaching hospital. Prescriptions between January 2018 and July 2019 were identified and inpatient records were analysed. OPTIMAL Calculator 2 was used as a gold standard for assessing conversion of oral dopaminergic medication to Rotigotine. RESULTS: a total of 84 inpatients were included. 25 (30%) patients were prescribed the recommended dose of Rotigotine; 31 (37%) higher and 28 (33%) lower than recommended. A total of 15 of 41 (37%) patients with dementia and 22 of 49 (45%) patients with delirium before initiation of Rotigotine inappropriately received the higher dose; 20 (24%) patients developed new/worsening delirium and 8 (10%) patients developed new/worsening hallucinations; and 59 (70%) patients were dead at time of evaluation, of these 40 (68%) died in hospital, 10 (25%) of whom experienced terminal agitation. CONCLUSIONS: acute conversion of oral dopaminergic medication to trans-dermal Rotigotine patch remains problematic despite the availability of validated tools. Inappropriate dosing may precipitate or worsen delirium/hallucinations. Use at end-of-life requires further evaluation.
引用
- Ibrahim H, Woodward Z, Pooley J, et al. Rotigotine patch prescription in inpatients with Parkinson's disease: evaluating prescription accuracy, delirium and end-of-life use. Age Ageing. 2021. PMID: 33264385. doi:10.1093/ageing/afaa256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。